{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104592","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.952624+00:00","generated_at":"2026-05-17T17:19:32.873879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028","bullets":["Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.","Cash, equivalents & short-term investments $177.2M at June 30, 2025 (vs $47.2M Dec 31, 2024).","IND filings on track: HWK-007 and HWK-016 by year-end 2025; HWK-206 by mid-2026.","Cash anticipated to fund operations into 2028, enabling initial clinical data readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104592","json":"https://secwatch.observer/filing/0000950170-25-104592.json","markdown":"https://secwatch.observer/filing/0000950170-25-104592.md","text":"https://secwatch.observer/filing/0000950170-25-104592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/0000950170-25-104592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/whwk-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:19:32.873879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}